Congleton Jon 4

What Happened
Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold a total of 75,000 shares in open‑market transactions on March 31, 2026, generating aggregate proceeds of approximately $1,970,522. The sale consisted of 19,364 shares at a weighted‑average price of $25.50 ($493,794), 55,183 shares at a weighted‑average price of $26.54 ($1,464,474), and 453 shares at a weighted‑average price of $27.05 ($12,254). These were sales (not purchases) and thus are generally considered liquidity moves rather than a direct bullish signal.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 2, 2026 (appears timely under the SEC two‑business‑day rule).
• Aggregate shares sold: 75,000; aggregate proceeds: ~$1.97 million.
• Reported prices (weighted averages): $25.50, $26.54, $27.05. Price ranges per filing: $25.00–$25.9994; $26.00–$26.9999; $27.00–$27.10. The filer can provide a per‑share price breakdown on request (see footnotes).
• Footnote: Transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted December 30, 2025.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• A 10b5‑1 plan allows insiders to sell according to a prearranged schedule and is commonly used to avoid questions about trading on inside information; it does not necessarily indicate a change in the insider’s view of the company.
• These were outright sales (transaction code S). For retail investors, purchases by insiders often carry more interpretive weight than routine sales executed under 10b5‑1 plans.